China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) has announced that its controlled subsidiary, Henan Zhongshuai Pharmaceutical Technology Co., Ltd. (referred to as "Zhongshuai Pharma"), recently received a Drug GMP Compliance Inspection Notification Letter issued by the Henan Provincial Medical Products Administration.
The product involved is Acetazolamide Sustained-Release Capsules (specification: 0.5g, National Drug Approval Number H20265455). The solid preparation workshop and the capsule production line passed this drug GMP compliance inspection.
Acetazolamide Sustained-Release Capsules are the first drug approved in China for the prevention or improvement of acute mountain sickness. It was approved for market launch in August 2026 and has not yet generated market sales.
Comments